Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Imaging microscopy shows killer T-cells targeting SARS-CoV-2 spike protein

Researchers demonstrate how cytotoxic T-lymphocytes (CTLs) with specificity for SARS-CoV-2 eliminate multiple infected targets.

30 Jan 2022

Adults and children have similar neutralizing antibody responses to SARS-CoV-2 infection

Researchers describe the kinetics of SARS-CoV-2-specific serum antibodies in convalescent children over six months following infection.

30 Jan 2022

Mix-and-match of COVID-19 vaccine boosters found to be safe and effective

In adults who had previously received a full regimen of a COVID-19 vaccine approved or authorized by the Food and Drug Administration (FDA), an additional dose of any of these COVID-19 vaccines was safe and prompted an immune response, according to study findings published Jan. 26 in The New England Journal of Medicine.

28 Jan 2022

UK's most vulnerable will soon be able to access second ground-breaking antiviral

Thousands of the country's most vulnerable will be able to access the UK's second ground-breaking antiviral - Pfizer's PF-07321332+ritonavir (Paxlovid) - from Thursday 10 February, the government has announced today.

28 Jan 2022

Novel “prime and spike” vaccine strategy leverages existing immunity generated by primary COVID-19 vaccination

Scientists from Yale University, USA, have recently developed an intranasal spike boosting vaccine that induces robust mucosal immunity in the respiratory tract,

28 Jan 2022

A synthesis of evidence sheds light on major immune components and mechanisms involved in COVID-19

New research highlights principal host factors that may explain the immune responses to SARS-CoV-2 and its variants in the context of infection susceptibility, disease severity, and previous immunity.

28 Jan 2022

Reduced neutralization against Omicron variant in fully immunized adolescents with BNT162b2 vaccine

Researchers compare the humoral immune response in adolescents and adults after being completely immunized with the Pfizer BNT162b2 vaccine.

28 Jan 2022

Study demonstrates minimally invasive, aerosolized vaccine candidate to combat SARS-CoV-2

This study showed inhalable Covid-19 mimetic particle carriers as potential, versatile, aerosolizable COVID-19 vaccine candidates if worked on with continued optimization and refinement.

28 Jan 2022

Exploring receptor-blocking conserved non-neutralizing antibodies for SARS-CoV-2 therapy

In a new study, researchers hypothesized and developed broad-spectrum SARS-CoV-2 inhibitors, ReconnAbs, by modifying the existing non-neutralizing antibodies targeted towards the highly conserved epitopes of the SARS-CoV-2 spike (S) protein combined with a receptor-blocking component.

28 Jan 2022

E406W mutation on SARS-CoV-2 RBD escapes monoclonal antibody cocktail-mediated neutralization

Researchers look to better understand the molecular basis of E406W-mediated escape from the REGEN-COV cocktail and cilgavimab.

28 Jan 2022

New trial tests the effectiveness of hyperimmune immunoglobulin for hospitalized COVID-19 patients

This scanning electron microscope image shows SARS-CoV-2 (round gold particles) emerging from the surface of a cell cultured in the lab. SARS-CoV-2, also known as 2019-nCoV, is the virus that causes COVID-19.NIAID

28 Jan 2022

Diagnosing COVID-19 with the new isothermal amplification technology

Announcing a new article publication for Zoonoses journal. During the COVID-19 pandemic, polymerase chain reaction (PCR) has become the gold standard for the detection of SARS-CoV-2 RNA worldwide.

28 Jan 2022

Novel molecular signaling pathway plays a key role in producing osteoarthritis pain

Researchers from North Carolina State University have discovered that a particular molecular signaling pathway plays an important role in producing osteoarthritis (OA) pain.

27 Jan 2022

Structural proteomics approaches can help in the treatment of neurodegenerative diseases

Two researchers from Skoltech and McGill University have published a review of the promising research field known as structural proteomics in the influential journal Chemical Reviews.

27 Jan 2022

Early-stage alveolar epithelial cell necrosis linked to COVID-19-induced acute respiratory distress syndrome

A new study analyzed whether alveolar epithelial cell necrosis at an early stage SARS-CoV-2 infection and subsequent releases of damage-associated molecular patterns could aggravate COVID-19-associated acute respiratory distress syndrome.

27 Jan 2022

Scientists identify immunogens that can elicit antibody responses against multiple SARS-CoV-2 variants

In a new study, researchers identified conserved sites in the SARS-CoV-2 spike protein using structural and sequence data, and then combined the results with existing deep mutational scanning data to design six antigens that can offer protection against significant immune escape mutations in the SARS-CoV-2 receptor-binding domain.

27 Jan 2022

Targeting CHI3L1 inhibits SARS-CoV-2 variants, including Delta and Omicron

Researchers show that the CHI3L1 inhibitors reduce epithelial cell infection by SARS-CoV-2 VOC pseudovirus moieties.

27 Jan 2022

Evaluating the effectiveness of vaccination on the case fatality rate for COVID-19 infection

A recent study was published where CFR was assessed for COVID-19 vaccine effectivity

27 Jan 2022

Omicron RBD mutations increase ACE2 binding and reduce antibody sensitivity

In a study conducted at the Florida International University, USA, scientists have investigated the impact of spike receptor-binding domain (RBD) mutations of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) omicron variant on its interaction with human angiotensin-converting enzyme 2 (ACE2).

26 Jan 2022

Recipients of inactivated COVID-19 vaccine (CoronaVac) can be successfully boosted with different vaccines

In the recently published study in The Lancet, first-authored by Dr. Sue Ann Costa Clemens from the University of Oxford in the United Kingdom and the University of Siena in Italy, a comprehensive analysis has been pursued on the immunogenicity and safety of both homologous and heterologous boosting after receiving the inactivated vaccine CoronaVac.

26 Jan 2022

Antibody News and Research

Further Reading

Imaging microscopy shows killer T-cells targeting SARS-CoV-2 spike protein

Adults and children have similar neutralizing antibody responses to SARS-CoV-2 infection

Mix-and-match of COVID-19 vaccine boosters found to be safe and effective

UK's most vulnerable will soon be able to access second ground-breaking antiviral

Novel “prime and spike” vaccine strategy leverages existing immunity generated by primary COVID-19 vaccination

A synthesis of evidence sheds light on major immune components and mechanisms involved in COVID-19

Reduced neutralization against Omicron variant in fully immunized adolescents with BNT162b2 vaccine

Study demonstrates minimally invasive, aerosolized vaccine candidate to combat SARS-CoV-2

Exploring receptor-blocking conserved non-neutralizing antibodies for SARS-CoV-2 therapy

E406W mutation on SARS-CoV-2 RBD escapes monoclonal antibody cocktail-mediated neutralization

New trial tests the effectiveness of hyperimmune immunoglobulin for hospitalized COVID-19 patients

Diagnosing COVID-19 with the new isothermal amplification technology

Novel molecular signaling pathway plays a key role in producing osteoarthritis pain

Structural proteomics approaches can help in the treatment of neurodegenerative diseases

Early-stage alveolar epithelial cell necrosis linked to COVID-19-induced acute respiratory distress syndrome

Scientists identify immunogens that can elicit antibody responses against multiple SARS-CoV-2 variants

Targeting CHI3L1 inhibits SARS-CoV-2 variants, including Delta and Omicron

Evaluating the effectiveness of vaccination on the case fatality rate for COVID-19 infection

Omicron RBD mutations increase ACE2 binding and reduce antibody sensitivity

Recipients of inactivated COVID-19 vaccine (CoronaVac) can be successfully boosted with different vaccines

Accelerating therapeutic antibody discovery and development eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo